We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aeglea BioTherapeutics Inc | NASDAQ:AGLE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.01 | 11.20 | 14.00 | 0 | 01:00:00 |
Presentation Details
Date: June 8-12, 2020 Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer Location: https://www.bio.org/events/bio-digital
The presentation will be available for download on the Presentations & Events section of the Company’s website and also will be available on-demand to registered participants of BIO Digital at https://www.bio.org/events/bio-digital/sessions/620997.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company received approval of its Clinical Trial Application (CTA) for ACN00177 for the treatment of Homocystinuria by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.
Media Contact:Kelly Boothe, Ph.D.Director, Corporate CommunicationsAeglea BioTherapeutics 512.399.5458 media@aegleabio.com
Investor Contact:Joey PerroneSenior Director, Finance & Investor RelationsAeglea BioTherapeuticsinvestors@aegleabio.com
1 Year Aeglea BioTherapeutics Chart |
1 Month Aeglea BioTherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions